evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract
14841,GENE_SUMMARY,,MAP2K2 encodes a kinase involved in the pro-oncogenic MAP-kinase signaling pathway. Mutation of MAP2K2 has been shown to confer resistance to MAP-kinase pathway targeted agents in melanoma.,,2017-02-21,,5605,MAP2K2,mitogen-activated protein kinase kinase 2,False,ENST00000262948,NM_030662.3,MKK2,PRKMK2,MAPKK2,CFC4,MEK2,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14842,GENE_BACKGROUND,,"MAP2K2 (mitogen-activated protein kinase kinase 2) encodes a dual specificity kinase referred to as MEK2 or MKK2 (PMID: 22753777). As a second component of a three-tiered MAP kinase cascade, MAP2K2 activity is dependent on phosphorylation of two serine residues (S222 and S226) catalyzed by upstream RAF kinases, members of the mitogen-activated protein kinase kinase kinase (MAPKKK) family. Activated MAP2K2 in turn phosphorylates ERKs (extracellular-signal-regulated kinases) (PMID: 22177953). These signaling events are triggered by growth factors, cytokines and hormones that activate upstream receptor tyrosine kinases, ultimately leading to altered expression of key regulators of cell growth, differentiation, proliferation and survival (PMID: 9069255, 11242034). Germline missense mutations and deletions in MAP2K2 are found in patients with cardio-facio-cutaneous syndrome (PMID: 20358587, 18456719, 21178588, 24311457, 23379592). Hyperactivation of the RAS/RAF/MEK/ERK pathway is frequently observed in human cancers; nevertheless, oncogenic mutations in MAP2K2 in primary tumors are infrequent (PMID: 24840079; cBioPortal, MSKCC, Apr. 2015). Because of its major role in signaling as a RAF oncogene effector, several inhibitors of wildtype MAP2K2 and its close structural and functional homologue, MAP2K1, have been developed (PMID: 20149254, 24840079). Trametinib has been approved for treatment of BRAF V600E/K positive melanoma (PMID: 22663011, US FDA NDA 204114). Point mutations in MAP2K2 are often identified in BRAF positive melanomas insensitive to RAF and MEK inhibitors and are thought to be responsible for the resistance to MAPK pathway targeted agents (PMID: 24265153, 24055054, 22197931).",,2017-02-21,,5605,MAP2K2,mitogen-activated protein kinase kinase 2,False,ENST00000262948,NM_030662.3,MKK2,PRKMK2,MAPKK2,CFC4,MEK2,False,18456719,Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.,Journal of medical genetics,2018-08-01T20:08:00,45,8,500-6,Nyström AM et al,doi: 10.1136/jmg.2008.057653,,0001-08-01,,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,Nature genetics,2017-12-25T20:11:00,44,2,133-9,Nikolaev SI et al,doi: 10.1038/ng.1026,,0001-12-25,,9069255,Mitogen-activated protein kinase pathways.,Current opinion in cell biology,0001-04-01,9,2,180-6,Robinson MJ et al,,,0001-04-01,,24840079,The clinical development of MEK inhibitors.,Nature reviews. Clinical oncology,2018-07-01T20:14:00,11,7,385-400,Zhao Y et al,doi: 10.1038/nrclinonc.2014.83,,2018-07-01T04:00:00,,20149254,From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.,Journal of hematology &amp; oncology,2018-02-11T20:10:00,3,,8,Frémin C et al,8722-03-08,,0001-02-11,,24311457,Multiple café au lait spots in familial patients with MAP2K2 mutation.,American journal of medical genetics. Part A,2018-02-01T20:14:00,164A,2,392-6,Takenouchi T et al,doi: 10.1002/ajmg.a.36288,,0001-02-01,,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,Cancer discovery,2018-01-01T20:14:00,4,True,94-109,Van Allen EM et al,doi: 10.1158/2159-8290.CD-13-0617,,2018-01-01T01:09:00,,22753777,MEK genomics in development and disease.,Briefings in functional genomics,2018-07-01T20:12:00,11,4,300-10,Bromberg-White JL et al,doi: 10.1093/bfgp/els022,,0001-07-01,,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,The New England journal of medicine,2018-07-12T20:12:00,367,2,107-14,Flaherty KT et al,doi: 10.1056/NEJMoa1203421,,0001-07-12,,21178588,Cardiofaciocutaneous syndrome in a mother and two sons with a MEK2 mutation.,Clinical dysmorphology,2018-04-01T20:11:00,20,2,1986-08-01,Linden HC et al,doi: 10.1097/MCD.0b013e32833ff29d,,0001-04-01,,24055054,Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.,Cell reports,2018-09-26T20:13:00,4,6,1090-9,Villanueva J et al,doi: 10.1016/j.celrep.2013.08.023,,0001-09-26,,20358587,Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.,American journal of medical genetics. Part A,2018-04-01T20:10:00,152A,4,807-14,Rauen KA et al,doi: 10.1002/ajmg.a.33342,,0001-04-01,,11242034,Mammalian MAP kinase signalling cascades.,Nature,2018-03-01T20:01:00,410,6824,37-40,Chang L et al,,,0001-03-01,,22177953,MEK1/2 dual-specificity protein kinases: structure and regulation.,Biochemical and biophysical research communications,2018-01-06T20:12:00,417,True,2001-05-10,Roskoski R Jr,doi: 10.1016/j.bbrc.2011.11.145,,0001-01-06,,23379592,Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?,Clinical genetics,2018-02-01T20:14:00,85,2,138-46,Nowaczyk MJ et al,doi: 10.1111/cge.12116,,0001-02-01,
